



Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19)

I would like to begin by offering my thoughts and prayers for those affected with the novel coronavirus and my deepest wishes for your rapid recovery.

As novel coronavirus infections spread around the world, our foremost priority is the continued delivery of treatments for visual conditions to our patients worldwide. As a life-science company making a contribution to society, we also have both a responsibility to avoid activities that will contribute to the further spread of the virus and a responsibility to continue innovations that will provide future benefits in eye disease treatment despite this challenging situation. In accordance with these fundamental policies, we are making every possible effort to comply with the regulations and guidance in place in various nations and regions of our business bases, including Japan, China and other Asian countries, Europe, and the US, as we implement the policies below.

【Measures in place at Santen's business bases worldwide, including Japan】

- Measures to secure a stable supply of our products
 - Ensuring safety in our plants (the provision of a sanitized environment through measures including wearing masks and disinfection with alcohol, thorough implementation of body temperature checks and maintenance of distance between employees)
 - Maintenance of appropriate inventory standards of intermediaries and raw materials
 - Provision of an environment for non-plant-based employees involved in production that allows working from home

- Measures to prevent the spread of the virus
 - All employees in all countries are fundamentally banned from traveling overseas
 - All employees in all countries are fundamentally banned from domestic business trips (As an exception, when there may occur any impact on the business or relationships with third parties require domestic business trip, it must be approved in advance by a supervisor)
 - Non-plant-based employees will basically work from home where possible (we began taking this measure even before it was required under the laws and regulations of various nations. We took this action in China on February 10, in other Asian nations on February 11, in Japan on February 25, in the US on March 9, and in European nations on March 13). Note that in cases where working from home is impossible due to the nature of the work or when traveling outside is absolutely necessary, employees are required to avoid congestion by traveling at non-peak times. Advance permission from supervisor is also required.
 - Providing supplies such as masks and goggles to employees in Japan, Europe, and the US and other parts of the world (we prioritize employees working at our plants, research centers, and employees who have contact during work with third parties. We are gradually expanding this distribution to include all employees including those at headquarters)
 - We are also ramping up efforts to educate and improve awareness among employees on the fundamental measures required to avoid contracting the virus

- Initiatives for the achievement of innovations in ophthalmology
 - Discussions with regulatory authorities on how to achieve safety while continuing to conduct clinical trials and file new applications
 - Ensuring safety in our research centers (the provision of a sanitized environment through measures

including wearing masks and disinfection with alcohol, thorough implementation of body temperature checks and maintenance of distance between employees)

- Working to implement a system that would allow employees to continue to provide information to healthcare professionals even when working from home

【Other measures】

- We have set up a crisis management committee led by the company president. The committee will monitor the situation in Japan and at our centers of operation around the world, discussing and issuing guidance on appropriate actions (from January 28)
- We are revising our pandemic business continuation plan (BCP) on the assumption of a more extensive, longer-lasting pandemic
- A donation of 1 million RMB (approximately ¥16 million) to the Chinese Red Cross

In China, we moved swiftly to arrange working from home in January as the novel coronavirus infections began to spread, banning business trips and traveling into work and taking thorough measures at our plants, and as a result, we have not at this time confirmed infections among our employees in China. Our plant in Suzhou, which has been fully operational since February 10, we are thankful to the City Mayor visited the plant and provided a statement of gratitude. As the pace of infections inside China appears to be decelerating, employees are continuing to work at home as we gradually loosen restrictions on working in offices.

We are committed to these ongoing efforts to maintain a safe stable product supply, avoid further spread of the virus, and continue working to achieve innovations in ophthalmological treatment so as not to interfere with its business activities.

It is my earnest hope that the international community can come together to find, as soon as possible, a path towards the resolution of the current novel coronavirus outbreak.

April 1, 2020

Shigeo Taniuchi
President, Chief Executive Officer
Santen Pharmaceutical Co., Ltd.

